Skip to main
HUMA

Humacyte (HUMA) Stock Forecast & Price Target

Humacyte (HUMA) Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 57%
Buy 29%
Hold 14%
Sell 0%
Strong Sell 0%

Bulls say

Humacyte is well-positioned for long-term success with a strong pipeline of products in high-demand markets and technology that has proven to be safe and effective. Additionally, the company has successfully navigated challenges in obtaining reimbursement for their products and has recently announced a partnership with the VA. Financially, the company is in a strong position with recent cost-cutting measures and an equity offering providing necessary capital to support future growth and development. Risks to the company's success include potential clinical setbacks and competition in the biotechnology market.

Bears say

Humacyte is a biotechnology company with a promising pipeline of products that aim to address significant medical needs and potentially transform the practice of medicine. Despite a potential market opportunity in dialysis, the company may face challenges in gaining regulatory approval and market acceptance, as well as achieving profitability. The recent announcement of a joint venture in Saudi Arabia may provide further revenue opportunities, but geopolitical conflicts in the region could pose logistical challenges for the company. Additionally, with a relatively small market cap and a history of operating losses, investors should approach this stock with caution and carefully consider the risks associated with investing in a microcap healthcare company.

Humacyte (HUMA) has been analyzed by 7 analysts, with a consensus rating of Buy. 57% of analysts recommend a Strong Buy, 29% recommend Buy, 14% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Humacyte and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Humacyte (HUMA) Forecast

Analysts have given Humacyte (HUMA) a Buy based on their latest research and market trends.

According to 7 analysts, Humacyte (HUMA) has a Buy consensus rating as of Jun 26, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $5.25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $5.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Humacyte (HUMA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.